Ocular Therapeutix (OCUL) Misses Q4 EPS by 4c

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.42), $0.04 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $504 thousand versus the consensus estimate of $480 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance